Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 37 for:    Open Studies | "Arthritis, Juvenile Rheumatoid"
Previous Study | Return to List | Next Study

Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by AbbVie
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: August 5, 2011
Last updated: April 7, 2017
Last verified: April 2017

This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug:

  • Unknown adverse drug reactions (especially important adverse drug reactions)
  • Incidence and conditions of occurrence of adverse reactions in the clinical setting
  • Factors that may affect the safety and effectiveness of Humira

Arthritis, Juvenile Rheumatoid

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Number of patients with adverse drug reactions [ Time Frame: at week 24 ]
    Occurrence of adverse event (yes or no), nature of adverse drug reactions, date of onset, seriousness, clinical course of adverse drug reactions, outcome, measures, causal relationship between the adverse drug reactions and Humira

  • Disease Activity Score28 [ Time Frame: at week 4 ]
  • Disease Activity Score28 [ Time Frame: at week 8 ]
  • Disease Activity Score28 [ Time Frame: at week 12 ]
  • Disease Activity Score28 [ Time Frame: at week 16 ]
  • Disease Activity Score28 [ Time Frame: at week 24 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 4 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 8 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 12 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 16 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 24 ]
  • Height [ Time Frame: at week 4 ]
  • Height [ Time Frame: at week 8 ]
  • Height [ Time Frame: at week 12 ]
  • Height [ Time Frame: at week 16 ]
  • Height [ Time Frame: at week 24 ]
  • Weight [ Time Frame: at week 4 ]
  • Weight [ Time Frame: at week 8 ]
  • Weight [ Time Frame: at week 12 ]
  • Weight [ Time Frame: at week 16 ]
  • Weight [ Time Frame: at week 24 ]
  • Anti-cyclic citrullinated peptides antibodies [ Time Frame: at baseline ]
  • Anti-cyclic citrullinated peptides antibodies [ Time Frame: at week 24 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 4 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 8 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 12 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 16 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 24 ]

Estimated Enrollment: 100
Study Start Date: August 2011
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
those with an exposure


Ages Eligible for Study:   up to 99 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
- All patients who receive Humira for the treatment of Juvenile idiopathic arthritis

Inclusion Criteria:

- All patients with Juvenile idiopathic arthritis who are not responding well to conventional therapy and receive Humira will be enrolled in the survey

Exclusion Criteria:

  • Contraindications according to the Package Insert
  • Patients who have serious infections
  • Patients who have tuberculosis
  • Patients with a history of hypersensitivity to any ingredient of Humira
  • Patients who have demyelinating disease or with a history of demyelinating disease
  • Patients who have congestive cardiac failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01412021

Contact: AbbVie_GK Clinical_Trials_Registration_Desk +81-3-4577-1125
Contact: Kaori Hozumi

  Show 152 Study Locations
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: Sarina Kurimoto AbbVie GK
  More Information

Additional Information:
Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT01412021     History of Changes
Other Study ID Numbers: P12-769
Study First Received: August 5, 2011
Last Updated: April 7, 2017

Keywords provided by AbbVie:
Arthritis, Juvenile Rheumatoid

Additional relevant MeSH terms:
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases processed this record on April 25, 2017